JACKSONVILLE, Fla.,
July 26, 2018 /PRNewswire/
-- The American Association of Clinical Endocrinologists
(AACE) today announced results of two recent online surveys,
conducted by The Harris Poll that assessed the attitudes of
endocrinologists and adults living with type 1 diabetes (T1D) in
the United States. The T1D
Unmet Needs surveys examined the support, management and
treatment of the disease and why it is important to continue
prioritizing and advancing innovation to help people achieve better
outcomes. More than 70 percent of endocrinologists and adults with
T1D surveyed stated that recent advances in T1D give them hope that
there will eventually be a cure, yet an overwhelming majority
agreed that more advances are currently needed to help improve the
lives of those with the disease. These national surveys were
supported by Lexicon Pharmaceuticals and Sanofi US.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8364251-aace-type-1-diabetes-management/
Specifically, these findings reveal:
- While 73 percent of both endocrinologists and adults with T1D
stated that recent advances in the T1D space give them hope for a
cure, they still seek more; with 87 percent of those with T1D and
93 percent of endocrinologists agreeing with the sentiment that
more advances are needed to improve the lives of those with
T1D.
- Additional data show that nearly all endocrinologists (97%)
said that their patients want options to help them better manage
their disease, with 82 percent of those with T1D in agreement.
"Over the past five years, the type 1 diabetes landscape has
vastly evolved. With new technology, genetic research and testing,
and finger stick-free monitoring devices, it's truly an exciting
and unprecedented time in healthcare, and in diabetes in
particular. However, the data from these surveys are an important
reminder that there is still a lot of work to be done to meet the
needs of the type 1 diabetes community," said George Grunberger, MD, FACP, FACE chairman at
Grunberger Diabetes Institute in Bloomfield Hills, Michigan. "Physicians should
ensure they are working in partnership with their patients to
review new research that might address both therapeutic and disease
management challenges."
Despite Progress, People Living with T1D Still Struggle with
the Impact the Disease Has on Their Lives
For those living with T1D, everyday situations that other people
take for granted can be challenging and ultimately have an adverse
impact on their lives. For instance, 88 percent of adults with T1D
said that living with the disease adds stress to their lives and
that they avoid going out to eat (57%) or attending social
gatherings with family and friends (49%) because of their
disease.
These challenges extend into disease management, as adults
living with T1D said they struggle the most with keeping their
blood sugar within recommended range (58%) and achieving
individualized target A1C levels (48%). Endocrinologists agreed
that these are the top things their patients struggle with.
Approximately 77 percent of adults with T1D wish they had a
medication to help them stay within the recommended blood sugar
range for longer periods of time. Endocrinologists are not immune
to the effects these challenges have on their patients as 93
percent wish there was more they could do for them.
"These findings highlight the ongoing need to provide support to
adults living with type 1 diabetes," said Rachele Berria, MD, PhD, head of US Diabetes
Medical Affairs at Sanofi. "We have collaborated with AACE and
Lexicon Pharmaceuticals to ensure these unmet needs are brought to
the forefront in the hopes that increased awareness will help to
transform care for people living with type 1 diabetes."
Opportunities Exist to Improve Education and Cross-Share
Knowledge
Almost all endocrinologists (97%) said they keep
their patients informed of advances in T1D and, overall, adults
with T1D and physicians were aligned in many aspects of their views
of T1D. However, opportunities exist to further align as evident by
some of the biggest gaps in knowledge including:
- Virtually all endocrinologists (99%) are knowledgeable about
non-insulin pathways, yet less than half (45%) of those with T1D
knew about them.
- Regarding other advances, one third of endocrinologists (32%)
believe "artificial pancreases" have the greatest potential for
positive impact on their patients with T1D but many adults living
with T1D (28%) don't know anything about that advancement.
"These findings represent an opportunity to enhance education
and cross-share information about innovation that might ultimately
improve type 1 diabetes care and outcomes," said Pablo Lapuerta, MD, executive vice president and
chief medical officer at Lexicon. "Lexicon and our partners at
Sanofi are committed to bettering the lives of the millions of
people around the world living with diabetes. We understand that
living with type 1 diabetes is an everyday challenge and through
our collaboration with AACE, we hope to call attention to the
unresolved needs of the type 1 diabetes community,
specifically."
For more information on the challenges faced by people living
with T1D, please visit gobeyondinsulinalonet1d.com.
About the Surveys
The research was conducted online by
The Harris Poll on behalf of The American Association of Clinical
Endocrinologists (AACE) in collaboration with Lexicon
Pharmaceuticals, Inc. and Sanofi, among patients diagnosed with
type 1 diabetes (T1D) and endocrinologists who treat T1D patients
within the United States. The
patient survey was conducted May 21 through
June 6, 2018 among 255 adults age 18+ who have been
diagnosed by a healthcare professional with T1D. Figures for
age by gender, income, race/ethnicity, region, size of household,
marital status and employment status were weighted where necessary
to bring them into line with their actual proportions in the
population. The healthcare professional survey was conducted
May 22 through June 11, 2018 among
253 endocrinologists who see at least one patient with T1D in a
month. Results were weighted for gender, by years in practice, and
by region where necessary to bring them into line with their actual
proportions in the population.
About American Association of Clinical Endocrinologists
(AACE)
The American Association of Clinical Endocrinologists (AACE)
represents more than 7,500 endocrinologists in the United States and abroad. AACE is the
largest association of clinical endocrinologists in the world. The
majority of AACE members are certified in endocrinology, diabetes
and metabolism and concentrate on the treatment of patients with
endocrine and metabolic disorders including diabetes, thyroid
disorders, osteoporosis, growth hormone deficiency, cholesterol
disorders, hypertension and obesity. Visit our site
at www.aace.com.
About Sanofi:
Sanofi (EURONEXT: SAN) (NYSE: SNY) is
dedicated to supporting people through their health challenges. We
are a global biopharmaceutical company focused on human health. We
prevent illness with vaccines, provide innovative treatments to
fight pain and ease suffering. We stand by the few who suffer from
rare diseases and the millions with long-term chronic
conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
About Lexicon Pharmaceuticals
Lexicon (NASDAQ: LXRX)
is a fully integrated biopharmaceutical company that is applying a
unique approach to gene science based on Nobel Prize-winning
technology to discover and develop precise medicines for patients
with serious, chronic conditions. Through its Genome5000™ program,
Lexicon scientists have studied the role and function of nearly
5,000 genes over the last 20 years and have identified more than
100 protein targets with significant therapeutic potential in a
range of diseases. Through the precise targeting of these proteins,
Lexicon is pioneering the discovery and development of innovative
medicines to safely and effectively treat disease. In addition to
its first commercial product for the treatment of carcinoid
syndrome, Lexicon has a pipeline of promising drug candidates in
clinical and pre-clinical development in diabetes and metabolism
and neuropathic pain. For additional information please visit
www.lexpharma.com.
Contact:
|
Glenn
Sebold
|
|
(904) 353-7878 ext.
122
|
|
gsebold@aace.com
|
View original
content:http://www.prnewswire.com/news-releases/new-insights-revealed-in-national-survey-show-more-advances-are-needed-for-the-type-1-diabetes-community-300686619.html
SOURCE The American Association of Clinical Endocrinologists
(AACE)